Viewed: 123
Emailed: 0
PDF Downloaded: 381
Full Text PDF Share on Facebook Share on Twitter
Original Article
Author Details :
Volume : 14, Issue : 1, Year : 2024
Article Page : 292-300
https://10.18231/j.pjms.2024.052
Abstract
Introduction: Sickle cell disease is one of the most common hemoglobinopathies in India. A vaso-occlusive crisis is one of the most common indications for hospitalization, it accounts for 70% of hospitalization.
Aim & Objective: To compare efficacy of Arginine in vaso-occlusive episode(VOE) management in terms of mean fall in pain score at discharge between intervention (Arginine) & placebo group among sickled children with skeletal vaso-occlusive crisis between 2-14 years of age.
Materials and and Methods: This randomized placebo control study was carried out after getting clearance from the institutional ethical & research committee, from November 2019 to October 2021 in the Indoor of Pediatrics Department, Veer Surendra Sai Institute of Medical Science (VIMSAR), Burla, Sambalpur.
Observation: There is significant fall in pain score in case group as compared with control group as evidenced by p value being less than 0.001, indicating that l-arginine has significant role in reducing sickle cell vaso-occlusive episode. Mean Length of stay (LOS) in hospital in case group was 2.16, while in control group was 2.69. p value being calculated showed the value to be less than 0.001, which shows importance of l-arginine in reducing in mean length of stay in hospitalization.
Conclusion: L-arginine plays a vital role in treating vaso-occlusive episodes. It helps to reduce the pain gradually as evidenced by noting down pain score at the time of admission & every 24 hours of therapy till discharge. It also helps to reduce the mean duration of hospitalization in vaso-occlusive episode.
Keywords: Arginine in sickle cell vaso-occlusive crisis: A randomised placebo control trial
How to cite : Majhi S C, Nayak H, Kiro S, Patil S, Meher S K, Panda S, Murmu M C, Arginine in sickle cell vaso-occlusive crisis: A randomised placebo control trial. Panacea J Med Sci 2024;14(1):292-300
Copyright © 2024 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)